News &amp; Updates

Keeping a healthy lifestyle such as having a balanced diet, regular exercise, and quality sleep may provide survival benefits to patients with cirrhosis, suggests a study.

Healthy behaviours may prevent death in cirrhosis patients

Budesonide outdoes mesalamine in treatment of microscopic colitis

Treatment with budesonide shows better clinical remission rates and fewer adverse events (AEs) than mesalamine in patients with microscopic colitis (MC), reveals a study.

Budesonide outdoes mesalamine in treatment of microscopic colitis

Primary sclerosing cholangitis an independent risk factor for colorectal cancer

01 Aug 2025

Primary sclerosing cholangitis (PSC) poses an increased risk of colorectal cancer (CRC), even in the absence of concomitant inflammatory bowel disease (IBD), according to a retrospective study.

Primary sclerosing cholangitis an independent risk factor for colorectal cancer

01 Aug 2025

Appendectomy provides no additional benefit in UC

31 Jul 2025

Appendectomy does not appear to alter the clinical course of patients with ulcerative colitis (UC), such that those who undergo the procedure are not more likely to experience a milder clinical course compared with those who choose not to, regardless of underlying appendicitis, as shown in a study.

Appendectomy provides no additional benefit in UC

31 Jul 2025

Vitamin D supplementation offers some benefits in IBD

Vitamin D supplementation appears to improve inflammatory bowel disease (IBD) outcomes, including related ED visits, hospitalizations, and corticosteroid use, according to a retrospective study.

Vitamin D supplementation offers some benefits in IBD

GLP-1 RAs up risks of GERD, complication vs SGLT-2 inhibitors

Compared with using SGLT-2 inhibitors, treatment with GLP-1 receptor agonists (RAs) may increase the risk for gastroesophageal reflux disease (GERD) and its complications in patients with type 2 diabetes (T2D), a recent study has shown.

GLP-1 RAs up risks of GERD, complication vs SGLT-2 inhibitors

Tulisokibart looks good for Crohn’s disease

19 Jul 2025

Induction treatment with the anti-TL1A monoclonal antibody tulisokibart appears to produce response in patients with moderately to severely active Crohn’s disease (CD) while being well tolerated, according to the results of a phase IIa trial.

Tulisokibart looks good for Crohn’s disease

19 Jul 2025

Coeliac disease risk increased among patient kin

17 Jul 2025

First-degree relatives (FDRs) of patients with coeliac disease (CD) are at an elevated risk of developing CD, suggests a study.

Coeliac disease risk increased among patient kin

17 Jul 2025

Hepatic steatosis linked to lower mortality in CLD patients

The presence of substantial hepatic steatosis estimated by controlled attenuated parameter (CAP) score among patients who underwent vibration-controlled transient elastography (VCTE) appears to reduce the risk of all-cause mortality and decompensation, particularly in those with metabolic dysfunction-associated steatotic liver disease (MASLD), reports a study.

Hepatic steatosis linked to lower mortality in CLD patients

Ustekinumab improves outcomes in UC patients

Treatment with ustekinumab can help patients with ulcerative colitis (UC) achieve clinical and endoscopic outcomes of importance after 12 months, results of a real-world study have shown.

Ustekinumab improves outcomes in UC patients